Shares of Medtronic PLC (NYSE:MDT) ended Monday session in green amid volatile trading. The shares closed up +0.78 points or 0.90% at $87.14 with 3.49 million shares getting traded. Post opening the session at $86.44, the shares hit an intraday low of $86.10 and an intraday high of $87.36 and the price vacillated in this range throughout the day. The company has a market cap of $120.31 billion and the numbers of outstanding shares have been calculated to be 1.38 billion shares.
Medtronic PLC (MDT) on Sept. 20, 2016 announced new data, demonstrating safety and efficacy at three years in acute complicated Type B aortic dissection patients treated with the Valiant® Captivia® Thoracic Stent Graft System. Ali Azizzadeh, MD, FACS, University of Texas Health Science Center in Texas presented the new clinical data in a late-breaking trial session at Vascular Interventional Advances (VIVA) 2016.
An acute aortic dissection is a serious condition in which the inner layer of the aorta tears, blood surges through the tear, and causes the inner and middle layers of the aorta to separate. This can result in aorta rupture or malperfusion of the vessels originating from the dissected aorta, leading to high morbidity and mortality. A type B dissection is a tear located in the descending aorta.
“Evidence shows that patients with acute complicated Type B aortic dissections can be safely and effectively treated with thoracic endovascular aortic repair (TEVAR),” said Dr. Azizzadeh. “The Valiant Captivia System continues to produce positive outcomes through three years in a very challenging patient population.”
Shares of Allergan plc Ordinary Shares (NYSE:AGN) ended Monday session in red amid volatile trading. The shares closed down -0.26 points or -0.11% at $238.41 with 3.97 million shares getting traded. Post opening the session at $238.78, the shares hit an intraday low of $234.26 and an intraday high of $240.41 and the price vacillated in this range throughout the day. The company has a market cap of $94.50 billion and the numbers of outstanding shares have been calculated to be 395.95 million shares.
Allergan plc Ordinary Shares (AGN) on Sept. 20, 2016 announced that the Company has acquired Akarna Therapeutics Ltd., a privately held biopharmaceutical company focused on developing novel small molecule therapeutics that target inflammatory and fibrotic diseases, for an up-front payment of $50 million, subject to certain adjustments, as well as potential clinical, regulatory and commercial milestone payments related to its lead development compound, AKN-083. In addition to AKN-083, the acquisition also includes a portfolio of additional development-stage FXR compounds.
Non-Alcoholic Steatohepatitis (NASH) is a severe type of non-alcoholic fatty liver disease (NAFLD), which is characterized by the accumulation of fat in the liver with no other apparent causes. NASH occurs when the accumulation of liver fat is accompanied by inflammation and cellular damage. The inflammation can lead to fibrosis (scarring) of the liver and eventually progress to cirrhosis, portal hypertension, liver cancer, and eventual liver failure NAFLD and NASH affect approximately 30% and 5%, respectively, of the US population and NAFLD affects more than 20% of the population worldwide.